| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Divisions of Surgery (ARM, VET, JS, MSK, ABC), Pathology (AA, I-TY, FES), and Radiology (PMO, CM, WTP), University of Texas Health Science Center at San Antonio, Texas.
Correspondence: Address correspondence and reprint requests to: Alexander R. Miller, MD, Department of Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229; Fax: 210-567-6862; E-mail: millerar{at}uthscsa.edu
Background: Sentinel lymph node mapping (SLNM) and neoadjuvant chemotherapy are becoming established components of therapy for selected patients with breast carcinoma. However, neoadjuvant therapy has been considered a relative contraindication to SLNM. In an effort to learn whether patients who have received preoperative chemotherapy can undergo accurate SLNM, we evaluated our experience with this technique.
Methods: From January 1997 to June 2000, SLNM and axillary lymph node dissection were concurrently performed in 35 patients who received preoperative chemotherapy. Mapping was performed with 99mTc sulfur colloid only in one patient and Lymphazurin dye only in 15 patients, and the two methods were combined in the remainder.
Results: SLNM successfully identified a sentinel lymph node in 30 (86%) patients. Metastatic disease was identified in the sentinel lymph nodes of four patients during surgery. The intraoperative pathologic diagnosis proved to be correct in 19 (79%) of 24 patients. The final pathologic diagnosis of the sentinel lymph node reflected the status of the axillary contents in all patients in whom it was identified.
Conclusions: These results demonstrate that SLNM can be consistently performed in patients receiving preoperative chemotherapy for breast cancer, suggesting the utility of this technique in this patient population.
Key Words: Breast cancer • Sentinel lymph node mapping • Neoadjuvant chemotherapy • Axillary lymph node dissection
This article has been cited by other articles:
 |
|
 |
|
  B. J. Grube, C. J. Christy, D. Black, M. Martel, L. Harris, J. Weidhaas, M. P. DiGiovanna, G. Chung, M. M. Abu-Khalaf, K. D. Miller, et al. Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy Arch Surg, July 1, 2008; 143(7): 692 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shimazu, Y. Tamaki, T. Taguchi, F. Tsukamoto, T. Kasugai, and S. Noguchi Intraoperative Frozen Section Analysis of Sentinel Lymph Node in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Ann. Surg. Oncol., June 1, 2008; 15(6): 1717 - 1722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gimbergues, C. Abrial, X. Durando, G. Le Bouedec, F. Cachin, F. Penault-Llorca, M. A. Mouret-Reynier, F. Kwiatkowski, J. Maublant, A. Tchirkov, et al. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation Ann. Surg. Oncol., May 1, 2008; 15(5): 1316 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Yu, G.-C. Hsu, C.-B. Hsieh, C.-P. Yu, and T.-Y. Chao Role of Sentinel Lymphadenectomy Combined with Intraoperative Ultrasound in the Assessment of Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy Ann. Surg. Oncol., January 1, 2007; 14(1): 174 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Cox, J. M. Cox, L. B. White, N. G. Stowell, J. D. Clark, N. Allred, M. Meyers, E. Dupont, B. Furman, and S. Minton Sentinel Node Biopsy Before Neoadjuvant Chemotherapy for Determining Axillary Status and Treatment Prognosis in Locally Advanced Breast Cancer Ann. Surg. Oncol., April 1, 2006; 13(4): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Khan, M. S. Sabel, A. Nees, K. M. Diehl, V. M. Cimmino, C. G. Kleer, A. F. Schott, D. F. Hayes, A. E. Chang, and L. A. Newman Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy Ann. Surg. Oncol., September 1, 2005; 12(9): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Mamounas, A. Brown, S. Anderson, R. Smith, T. Julian, B. Miller, H. D. Bear, C. B. Caldwell, A. P. Walker, W. M. Mikkelson, et al. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol., April 20, 2005; 23(12): 2694 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Newman, N. L. Pernick, V. Adsay, K. A. Carolin, P. I. Philip, S. Sipierski, D. L. Bouwman, M. A. Kosir, M. White, and D. W. Visscher Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated With Preoperative Chemotherapy Correlates With Breast Cancer Outcome Ann. Surg. Oncol., August 1, 2003; 10(7): 734 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Bland Utilization of Sentinel Lymph Node Mapping to Determine Pathologic Outcomes for Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Ann. Surg. Oncol., April 1, 2002; 9(3): 217 - 219. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
